Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Glasgow, Scotland, August 5, 2026 Mironid has successfully raised $46 million in a Series B financing round to accelerate...
Berlin, Germany | July 21, 2026 OMEICOS announced that the U.S. Food and Drug Administration (FDA) has provided positive...
TEL AVIV, Israel & OSLO, Norway, July 20, 2026 BioLineRx Ltd. and Hemispherian AS have announced that new preclinical...
STOCKHOLM, Sweden, July 1, 2026 AlzeCure Pharma AB has announced a landmark global out-licensing and collaboration agreement with Danish...
CAMBRIDGE, Mass., May 6, 2026 Clear Scientific Inc., a clinical-stage biopharmaceutical company developing innovative therapies for acute drug intoxication,...
WILMINGTON, DE — November 21, 2025 — Telomir Pharmaceuticals announced new preclinical findings showing that its investigational compound Telomir-1...
